Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Ianalumab
Other

Ianalumab

Tracked across 1 events · 6 articles · First seen May 31, 2026 · Last active Jun 01, 2026

Sentiment
60
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 60
Tech
Novartis presents positive immunology data
Novartis presented new data from 31 abstracts across its immunology portfolio at the European Alliance of Associations for Rheumatology (EULAR) Congress in London from June 3-6, 2026. Key presentations included new data for Secukinumab>>> (secukinumab)…
Impact: Ianalumab is another drug from Novartis's pipeline, with interim results from Sjögren's Phase III extension study and Phase II data in systemic lupus erythematosus being presented. Positive results could accelerate its path to market.
May 31, 2026 · 6 articles
Key Actions (1)
85 Novartis presented interim results IanalumabNovartis presents positive...
NEWSDESK
Track Ianalumab live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.